Vita Therapeutics Bolsters Leadership to Advance Multiple Technology Platforms · BioBuzz
Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies to treat muscular dystrophies and solid tumors, today announced the hiring of Amy Wesa, PhD, as Senior Vice President of Preclinical and Translational Research, Alexandra (Xana) Capela, PhD, as Senior Vice President of Regulatory and IND Strategy, and Michael Kuo as Senior Vice President of Manufacturing. In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.
Source: biobuzz.io